EFTA02592731

From: jeffrey E. <[email protected]> Sent: Wednesday, October 8, 2014 10:33 PM To: A Barrett Subject: Re: Confidential: Early detection of Ebola ill try, also i started the conversatoin with =ark about splitting up the interest, he is open to the idea,=C240 but wanted someone smart to advise. that meanss he does't =ant to pay for advice. On Wed, Oct 8, 2014 at 6:28 PM, A Barre =t; wrote: =i Jeffrey, Any interest in helping on this. I kno= last time you and Francis did not hit it off. Nevertheless he has been su=cessful as a scientist and is really not a "people' person. Q=A0 He claims he can develop the tools to diagnose=Ebola before it becomes symtomatic. Ant=ony Barrett Begin forwarded message: <=div> From: Francis Barany Date: October 8, 2014 at 6:06:32 PM EDT To: An=hony Barrett Cc: Michael Gargano >=br>Subject: Confidential: Early detection of Ebola </=iv> Dear Anthony, I really appreciate your willingness to find a potential pathway to Bi=l Gates and the Gates Foundation. By way of introduction, I have been a Professor at Weill-Cornell for t=e last 30 years, and am best known for having invented the Ligas= Chain Reaction (LCR) and the Universal Array. I hold 46 issued=US patents, a number of which have led to commercial tests to diagnose genetic diseases (i.e. cystic fibrosis, MLPA tests, =ANSR for NIPD of trisomy), and identify diseases using DNA microarray= and targeted Next-Gen sequencing. Earlier this year, I re=eived the IFCC Award for Significant Contributions in Molecular Diagn=stics. I have been collaborating with Dr. Linnie Golightly of our Center for =lobal Health/Infectious Disease Division for the past decade, wo=king together closely to develop multiplexed PCR-LDR assays for Categ=ry A EFTA_R1_01775796 EFTA02592731 Biothreat agents, including all the major viral hemorrhagic fever viruses (VHF; ebolavirus, marburgvirus Crimean Cong= hemorrhagic fever virus, Lassa fever virus, Rift Valley fever v=rus, Dengue virus, and Yellow fever virus). (Kindly see b=low abstract of manuscript just being submitted). In addition, =n collaboration with Professor Soper at UNC, we have been building4)=A0micro-fabricated devices to rapidly detect pathogens. Most recently, we have begun designing micro-fabricated devices that w=ll allow for electronic detection, obviating the need for expens=ve hardware used in most fluorescent detection schemes (i.e. Taqman a=says). As such, we are poised to combine these technologie= for rapidly identifying and providing quantitative viral load fo= all the VHF, Variola, Malaria or other Category A pathogens directly=from a drop of blood, with the next level of such devices suitab=e for working in developing countries, and may be powered and run by a cell phone or smart device. • Current CDC approved EZ1-RT-=CR Taqman assay has LOD of 5,000 PFU/ml. This works when patient is=C24>febrile, i.e. has overt symptoms and may be contagious. • Next level of assay needs to=be > 100-fold more sensitive. We know how to address this issue. • This would allow for identif=cation of individuals with early viral replication in their blood 4>=804,before they are contagious, so they may be isolated, and further= early detection may improve outcomes. Would your contacts be able to help us, so in turn we may help protect=our country? Most appreciated, Francis & Linnie Dr. Francis Barany Dept of Microbiology & Immunology Box 62 Rm B-406 Weill Cornell Medical College innie o ig y, Associate Professor of Clinical Medicine and Microbiology & Immunology Center for Global Health Division of Infectious Diseases Weill Cornell Medical College A Multiplex PCR/LDR Assay for the Simultaneous Identification of =ategory A Infectious Pathogens: Agents of Viral Hemorrhagic Fever and=Variola Virus 2 EFTA_R1_01775797 EFTA02592732 Das S.1, Rundell M.S.2, Mirza A.H.2, Pingle M.R.2, Shigyo K.1, Garriso= A.R.3, Paragas J.4, Smith S. K.5, Olson V. A.5, Larone D.H.2, 6= Spitzer E.D.7, Barany F.2 and Golightly L.M.1, 2 1. Department of Medicine, Division of Infectious Diseases, Weill Medi=al College of Cornell University, New York, NY 2. Department of Microbiology and Immunology, Weill Medical College of=Cornell University, New York, NY 3. United States Army Medical Research Institute of Infectious Disease=, Frederick, MD. 4. Integrated Research Facility, Division of Clinical Research, =IAID, NIH, Ft. Detrick, MD 5. Poxvirus Team, Poxvirus and Rabies Branch, Division of High Consequ=nce Pathogens and Pathology, National Center of Emerging Zoonoti= and Infectious Diseases, Centers for Disease Control and Prevention,=C2*Atlanta, GA 6. Department of Pathology and Laboratory Medicine, Weill Medical Coll=ge of Cornell University, New York, NY 7. Department of Pathology, Stony Brook University Medical Center, Sto=y Brook, NY ABSTRACT CDC designated category A infectious agents pose a major risk to natio=al security and require special action for public health pr=paredness. They include viruses that cause viral hemorrhagic fe=er (VHF) syndrome as well as variola virus, the agent of smallpo=. VHF is characterized by hemorrhage and fever with multi- organ=C2*failure leading to high mortality and morbidity. Smallpox,=a prior scourge, has been eradicated for decades making it a par=icularly serious threat if released nefariously in the essentially no=-immune world population. Early detection of the causative agents =nd ability to distinguish them from other pathogens is essential to=C2Qcontain outbreaks, implement proper control measures and prevent=morbidity and mortality. We have developed a multiplex det=ction assay that uses several species-specific PCR primers to generate ampl=cons from multiple pathogens; these are then targeted in a ligas= detection reaction (LDR). The resultant fluorescently-lab=led ligation products are detected on a universal array enabling simultaneous identification of the pathogens. The assay wa= evaluated on 32 different isolates associated with VHF (ebolavirus,=C24>marburgvirus Crimean Congo hemorrhagic fever virus, Lassa fever =irus, Rift Valley fever virus, Dengue virus, and Yellow fever virus) as well as variola virus and vaccinia virus (the agent of smal=pox and its vaccine strain, respectively). The assay was a=Ie to detect all viruses tested including 8 sequences representative=C24>of different variola virus strains from the CDC repository. It does not cross react with other emerging zoonoses such =s monkeypox virus or cowpox virus, or six flaviviruses tested (St. Lo=is encephalitis virus, Murray Valley Encephalitis virus, Powassa= virus, Tick-borne encephalitis virus, West Nile virus and Japanese encephalitis virus). please note The information contained in this communication is 3 EFTA_R1_01775798 EFTA02592733 confidential, =ay be attorney-client privileged, may constitute inside information, an= is intended only for the use of the addressee. It is the property of.IEE Unauthorized use, disclosure or copying of this communication o= any part thereof is strictly prohibited and may be unlawful. If you ha=e received this communication in error, please notify us immediately by=br>return e-mail or by e-mail to [email protected] <mailto:[email protected]> , and destroy this communicat=on and all copies thereof, including all attachments. copyright -all ri=hts reserved 4 EFTA_R1_01775799 EFTA02592734